Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases

References

• O’Keefe GA, Rao NA. Vogt-Koyanagi-Harada disease. Surv Ophthalmol. 2017;Jan-Feb;62(1):1–25. doi:10.1016/j.survophthal.2016.05.002. Epub 2016 May 27. PMID: 27241814.
   PubMed Web of Science ®Google Scholar
• Greco A, Fusconi M, Gallo A, et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev. 2013;Sep;12(11):1033–1038. doi:10.1016/j.autrev.2013.01.004. Epub 2013 Apr 6. PMID: 23567866.
   PubMed Web of Science ®Google Scholar
• Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;Jul 7;6(1):255. doi:10.1038/s41392-021-00679-0. PMID: 34234112; PMCID: PMC8261820.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;Dec 3;383(23):2255–2273. doi:10.1056/NEJMra2026131. PMID: 33264547; PMCID: PMC7727315.
   PubMed Web of Science ®Google Scholar
• Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2021;Mar;170:1–25. doi:10.1016/j.addr.2020.12.011. Epub 2020 Dec 24. PMID: 33359141; PMCID: PMC7759095.
   PubMed Web of Science ®Google Scholar
• Kim M. Vogt-Koyanagi-Harada Syndrome following influenza vaccination. Indian J Ophthalmol. 2016;Jan;64(1):98. doi:10.4103/0301-4738.178141. PMID: 26953036; PMCID: PMC4821134.
   PubMed Web of Science ®Google Scholar
• Campos WR, Cenachi SPF, Soares MS, Gonçalves PF, Vasconcelos-Santos DV. Vogt-Koyanagi-Harada-like disease following yellow fever vaccination. Ocul Immunol Inflamm. 2021;Jan 2;29(1):124–127. doi:10.1080/09273948.2019.1661498. Epub 2019 Oct 11. PMID: 31603703.
   PubMed Web of Science ®Google Scholar
• Sood AB, O’Keefe G, Bui D, Jain N. Vogt-Koyanagi-Harada disease associated with hepatitis B vaccination. Ocul Immunol Inflamm. 2019;27(4):524–527. doi:10.1080/09273948.2018.1483520. Epub 2018 Jun 28. PMID: 29953303.
   PubMed Web of Science ®Google Scholar
• Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;Jan;27(1):89–95. doi:10.1016/j.cmi.2020.09.023. Epub 2020 Sep 23. PMID: 32979574; PMCID: PMC7510771.
   PubMed Web of Science ®Google Scholar
• Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;Apr;27(4):601–615. doi:10.1038/s41591-021-01283-z. Epub 2021 Mar 22. PMID: 33753937.
   PubMed Web of Science ®Google Scholar
• Roshanshad A, Ashraf MA, Roshanshad R, Kharmandar A, Zomorodian SA, Ashraf H. Ocular manifestations of patients with coronavirus disease 2019: a comprehensive review. J Ophthalmic Vis Res. 2021;Apr 29;16(2):234–247. doi:10.18502/jovr.v16i2.9087. PMID: 34055261; PMCID: PMC8126735.
   PubMed Web of Science ®Google Scholar
• Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;Oct;100:190–209. doi:10.1016/j.phrs.2015.08.003. Epub 2015 Aug 12. PMID: 26275795; PMCID: PMC7129276.
   PubMed Web of Science ®Google Scholar
• Toussirot É, Bereau M. Vaccination and induction of autoimmune diseases. Inflamm Allergy Drug Targets. 2015;14(2):94–98. doi:10.2174/1871528114666160105113046. PMID: 26728772.
   PubMedGoogle Scholar
• Baden LR, El Sahly HM, Essink B, et al., COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;Feb 4;384(5):403–416. doi:10.1056/NEJMoa2035389. Epub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al., C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;Dec 31;383(27):2603–2615. doi:10.1056/NEJMoa2034577. Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doğanay HL, Akova M, et al., CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;Jul 17;398(10296):213–222. doi:10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8. Erratum in: Lancet. 2022 Jan 29;399(10323):436. PMID: 34246358; PMCID: PMC8266301.
   PubMed Web of Science ®Google Scholar
• Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci. 2021;Sep 15;428:117607. doi:10.1016/j.jns.2021.117607. Epub 2021 Aug 3. PMID: 34365148; PMCID: PMC8330139.
   PubMed Web of Science ®Google Scholar
• Siegler JE, Klein P, Yaghi S, et al. Cerebral vein thrombosis with vaccine-induced immune thrombotic thrombocytopenia. Stroke. 2021;Aug;52(9):3045–3053. doi:10.1161/STROKEAHA.121.035613. Epub 2021 Jul 26. PMID: 34304601; PMCID: PMC8378439.
   PubMed Web of Science ®Google Scholar
• Román GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D. Acute Transverse Myelitis (ATM):clinical review of 43 patients with COVID-19-Associated ATM and 3 Post-Vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 Vaccine (AZD1222). Front Immunol. 2021;Apr 26;12:653786. doi:10.3389/fimmu.2021.653786. PMID: 33981305; PMCID: PMC8107358.
   PubMed Web of Science ®Google Scholar
• Araujo-Silva CA, Marcos AAA, Marinho PM, et al. Presumed SARS-CoV-2 viral particles in the human retina of patients with COVID-19. JAMA Ophthalmol. 2021;Jul;29:e212795. doi:10.1001/jamaophthalmol.2021.2795. Epub ahead of print. PMID: 34323931; PMCID: PMC8323055.
   Google Scholar
• Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm. 2020;Apr 2;28(3):391–395. doi:10.1080/09273948.2020.1738501. Epub 2020 Mar 16. PMID: 32175797; PMCID: PMC7103678.
   PubMed Web of Science ®Google Scholar
• Sanjay S, Mutalik D, Gowda S, Mahendradas P, Kawali A, Shetty R. Post Coronavirus Disease (COVID-19) reactivation of a quiescent unilateral anterior Uveitis. SN Compr Clin Med. 2021;Jun 7:1–5. doi: 10.1007/s42399-021-00985-2. Epub ahead of print. PMID: 34124585; PMCID: PMC8184259.
   Google Scholar
• Papasavvas I, Herbort CP Jr. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination. J Ophthalmic Inflamm Infect. 2021;Jul 5;11(1):21. doi:10.1186/s12348-021-00251-5. PMID: 34224024; PMCID: PMC8256412.
   PubMed Web of Science ®Google Scholar
• Saraceno JJF, Souza GM, Dos Santos Finamor LP, Nascimento HM, Belfort R Jr. Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine. Int J Retina Vitreous. 2021;Aug 30;7(1):49. doi:10.1186/s40942-021-00319-3. PMID: 34462013.
   PubMedGoogle Scholar
• Maleki A, Look-Why S, Manhapra A, Foster CS. COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: real or Coincidence? J Ophthalmic Vis Res. 2021;Jul 29;16(3):490–501. doi:10.18502/jovr.v16i3.9443. PMID: 34394876; PMCID: PMC8358769.
   PubMed Web of Science ®Google Scholar
• Koong LR, Chee WK, Toh ZH, Ng XL, Agrawal R, Ho SL. Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine. Ocul Immunol Inflamm. 2021;Sep;10:1–4. doi:10.1080/09273948.2021.1974492. Epub ahead of print. PMID: 34505819.
   Google Scholar
• Santamaria A, Chang J, Savarain C. SARS-CoV-2 among the Potential Viral Triggers for Vogt-Konayagi-Harada Disease: first Case Report and Literature Review. Ocul Immunol Inflamm. 2021;Aug;26:1–7. doi:10.1080/09273948.2021.1966052. Epub ahead of print. PMID: 34436960.
   Google Scholar
• Tom ES, McKay KM, Saraf SS. Bilateral Ampiginous Choroiditis following Presumed SARS-CoV-2 Infection. Case Rep Ophthalmol Med. 2021;Aug 5;2021:1646364. doi:10.1155/2021/1646364. PMID: 34367705; PMCID: PMC8346294.
   PubMed Web of Science ®Google Scholar
• Benito-Pascual B, Gegúndez JA, Díaz-Valle D, et al. Panuveitis and optic neuritis as a possible initial presentation of the Novel Coronavirus Disease 2019 (COVID-19). Ocul Immunol Inflamm. 2020;Aug 17;28(6):922–925. doi:10.1080/09273948.2020.1792512. PMID: 32870739.
   PubMed Web of Science ®Google Scholar
• de Souza EC, de Campos VE, Duker JS. Atypical unilateral multifocal choroiditis in a COVID-19 positive patient. Am J Ophthalmol Case Rep. 2021;Jun;22:101034. doi:10.1016/j.ajoc.2021.101034. Epub 2021 Feb 19. PMID: 33623832; PMCID: PMC7893242.
   PubMedGoogle Scholar
• Iriqat S, Yousef Q, Ereqat S. Clinical profile of COVID-19 patients presenting with Uveitis - A short case series. Int Med Case Rep J. 2021;Jun 23;14:421–427. doi:10.2147/IMCRJ.S312461. PMID: 34188557; PMCID: PMC8236274.
   PubMed Web of Science ®Google Scholar
• Providência J, Fonseca C, Henriques F, Proença R. Serpiginous choroiditis presenting after SARS-CoV-2 infection: a new immunological trigger? Eur J Ophthalmol. 2020;Dec;2:1120672120977817. doi:10.1177/1120672120977817. Epub ahead of print. PMID: 33267645.
   Google Scholar
• Ortiz-Seller A, Martínez Costa L, Hernández-Pons A, Valls Pascual E, Solves Alemany A, Albert-Fort M. Ophthalmic and neuro-ophthalmic manifestations of coronavirus Disease 2019 (COVID-19). Ocul Immunol Inflamm. 2020;Nov 16;28(8):1285–1289. doi:10.1080/09273948.2020.1817497. Epub 2020 Oct 6. PMID: 33021422.
   PubMed Web of Science ®Google Scholar
• Bettach E, Zadok D, Weill Y, Brosh K, Hanhart J. Bilateral anterior uveitis as a part of a multisystem inflammatory syndrome secondary to COVID-19 infection. J Med Virol. 2021;Jan;93(1):139–140. doi:10.1002/jmv.26229. Epub 2020 Sep 30. PMID: 32592496; PMCID: PMC7361787.
   PubMed Web of Science ®Google Scholar
• Norose K, Yano A, Wang XC, et al. Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;Jan;35(1):33–39. PMID: 8300361.
   PubMed Web of Science ®Google Scholar
• Ng XL, Betzler BK, Testi I, et al. Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm. 2021;Aug 18;29(6):1216–1224. doi:10.1080/09273948.2021.1976221. Epub 2021 Sep 24. PMID: 34559576; PMCID: PMC8477588.
   PubMed Web of Science ®Google Scholar
• Lee YK, Huang YH. Ocular manifestations after receiving COVID-19 vaccine: a systematic review. Vaccines (Basel). 2021;9(12):1404. doi:10.3390/vaccines9121404.Published 2021 Nov 27.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xiao X, Li F, Du L, Kijlstra A, Yang P. Increased IL-7 expression in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012;Feb 27;53(2):1012–1017. doi:10.1167/iovs.11-8505. PMID: 22247488.
   PubMed Web of Science ®Google Scholar
• Vega-Tapia F, Bustamante M, Valenzuela RA, Urzua CA, Cuitino L. miRNA landscape in pathogenesis and treatment of Vogt-Koyanagi-Harada disease. Front Cell Dev Biol. 2021;May 10;9:658514. doi:10.3389/fcell.2021.658514. PMID: 34041239; PMCID: PMC8141569.
   PubMed Web of Science ®Google Scholar
• Chi W, Yang P, Li B, et al. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 2007;May;119(5):1218–1224. doi:10.1016/j.jaci.2007.01.010. Epub 2007 Mar 1. PMID: 17335887.
   PubMed Web of Science ®Google Scholar
• Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;Jul;21(7):939–949. doi:10.1016/S1473-3099(21)00224-3. Epub 2021 Apr 27. PMID: 33930320; PMCID: PMC8078878.
   PubMed Web of Science ®Google Scholar
• Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;Mar 20;397(10279):1057–1058. doi:10.1016/S0140-6736(21)00501-8. Epub 2021 Feb 25. PMID: 33640038; PMCID: PMC7972310.
   PubMed Web of Science ®Google Scholar
• Wise J. Covid-19: people who have had infection might only need one dose of mRNA vaccine. BMJ. 2021;Feb 2;372(n308). doi:10.1136/bmj.n308. PMID: 33531333.
   Google Scholar